Ongoing Research Projects

Mechanistic studies are focused on uncovering novel pathologic mechanisms of mitochondrial proteins involved in mitochondrial dynamics, quality control, cristae maintenance, and programmed cell death. These studies utilize novel cell and small animal models of brain injury in transgenic mice to evaluate mitochondrial dysfunction.

In addition to studying the mechanisms of mitochondrial dynamics and quality control, we are developing novel tools and techniques for the evaluation and quantification of these complex biological processes. Current work is focused on applying machine learning and agent-based modeling to the field of mitochondrial biology.

One area of focus is the development and clinical translation of neuroprotective therapies that reduce brain injury. Pre-clinical large animal studies are ongoing to evaluate novel therapeutic strategies that limit mitochondrial hyperactivity and prevent reactive oxygen species (ROS) production following brain injury. Translational projects are focused on cerebral ischemia/reperfusion injury (e.g. cardiac arrest, focal ischemic stroke, and newborn hypoxia) and traumatic brain injury (TBI). Additionally, our basic science project under the M-RISE center for resuscitation research is developing, testing, and translating novel therapeutic approaches to limit post-ischemic brain injury following resuscitation from cardiac arrest.

Together with our collaborators in the Heuttemann Lab, we are developing and testing a non-invasive therapeutic approach that uses near-infrared (NIR) light to modulate mitochondrial function by reducing the activity of cytochrome c oxidase. This approach allows non-pharmacologic modulation of disease processes that drive cerebral ischemia/reperfusion injury. This research has resulted in three awarded US patents, which formed the foundation of the startup company, Mitovation, Inc. The Sanderson Lab is investigating the detailed mechanism of action of NIR therapy and optimizing its use for treating cerebral ischemia/reperfusion injury. Mitovaiton, Inc. is translating this therapy to limit brain injury in infants resuscitated from cardiac arrest.